Colon cancer, version 3.2014

Al B. Benson, Alan P. Venook, Tanios Bekaii-Saab, Emily Chan, Yi Jen Chen, Harry S. Cooper, Paul F. Engstrom, Peter C. Enzinger, Moon J. Fenton, Charles S. Fuchs, Jean L. Grem, Steven Hunt, Ahmed Kamel, Lucille A. Leong, Edward Lin, Wells Messersmith, Mary F. Mulcahy, James D. Murphy, Steven Nurkin, Eric RohrenDavid P. Ryan, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Kristina M. Gregory, Deborah A. Freedman-Cass

Research output: Contribution to journalArticle

141 Citations (Scopus)

Abstract

The NCCN Guidelines for Colon Cancer address diagnosis, pathologic staging, surgical management, perioperative treatment, posttreatment surveillance, management of recurrent and metastatic disease,and survivorship. This portion of the guidelines focuses on the use of systemic therapy in metastatic disease. The management of metastatic colorectal cancer involves a continuum of care in which patients are exposed sequentially to a variety of active agents, either in combinations or as single agents. Choice of therapy is based on the goals of treatment, the type and timing of prior therapy, the different efficacy and toxicity profiles of the drugs, the mutational status of the tumor, and patient preference.

Original languageEnglish (US)
Pages (from-to)1028-1059
Number of pages32
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume12
Issue number7
DOIs
StatePublished - Jul 1 2014

Fingerprint

Colonic Neoplasms
Guidelines
Therapeutics
Continuity of Patient Care
Patient Preference
Drug-Related Side Effects and Adverse Reactions
Colorectal Neoplasms
Survival Rate
Neoplasms

ASJC Scopus subject areas

  • Oncology

Cite this

Benson, A. B., Venook, A. P., Bekaii-Saab, T., Chan, E., Chen, Y. J., Cooper, H. S., ... Freedman-Cass, D. A. (2014). Colon cancer, version 3.2014. JNCCN Journal of the National Comprehensive Cancer Network, 12(7), 1028-1059. https://doi.org/10.6004/jnccn.2014.0099

Colon cancer, version 3.2014. / Benson, Al B.; Venook, Alan P.; Bekaii-Saab, Tanios; Chan, Emily; Chen, Yi Jen; Cooper, Harry S.; Engstrom, Paul F.; Enzinger, Peter C.; Fenton, Moon J.; Fuchs, Charles S.; Grem, Jean L.; Hunt, Steven; Kamel, Ahmed; Leong, Lucille A.; Lin, Edward; Messersmith, Wells; Mulcahy, Mary F.; Murphy, James D.; Nurkin, Steven; Rohren, Eric; Ryan, David P.; Saltz, Leonard; Sharma, Sunil; Shibata, David; Skibber, John M.; Sofocleous, Constantinos T.; Stoffel, Elena M.; Stotsky-Himelfarb, Eden; Willett, Christopher G.; Gregory, Kristina M.; Freedman-Cass, Deborah A.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 12, No. 7, 01.07.2014, p. 1028-1059.

Research output: Contribution to journalArticle

Benson, AB, Venook, AP, Bekaii-Saab, T, Chan, E, Chen, YJ, Cooper, HS, Engstrom, PF, Enzinger, PC, Fenton, MJ, Fuchs, CS, Grem, JL, Hunt, S, Kamel, A, Leong, LA, Lin, E, Messersmith, W, Mulcahy, MF, Murphy, JD, Nurkin, S, Rohren, E, Ryan, DP, Saltz, L, Sharma, S, Shibata, D, Skibber, JM, Sofocleous, CT, Stoffel, EM, Stotsky-Himelfarb, E, Willett, CG, Gregory, KM & Freedman-Cass, DA 2014, 'Colon cancer, version 3.2014', JNCCN Journal of the National Comprehensive Cancer Network, vol. 12, no. 7, pp. 1028-1059. https://doi.org/10.6004/jnccn.2014.0099
Benson AB, Venook AP, Bekaii-Saab T, Chan E, Chen YJ, Cooper HS et al. Colon cancer, version 3.2014. JNCCN Journal of the National Comprehensive Cancer Network. 2014 Jul 1;12(7):1028-1059. https://doi.org/10.6004/jnccn.2014.0099
Benson, Al B. ; Venook, Alan P. ; Bekaii-Saab, Tanios ; Chan, Emily ; Chen, Yi Jen ; Cooper, Harry S. ; Engstrom, Paul F. ; Enzinger, Peter C. ; Fenton, Moon J. ; Fuchs, Charles S. ; Grem, Jean L. ; Hunt, Steven ; Kamel, Ahmed ; Leong, Lucille A. ; Lin, Edward ; Messersmith, Wells ; Mulcahy, Mary F. ; Murphy, James D. ; Nurkin, Steven ; Rohren, Eric ; Ryan, David P. ; Saltz, Leonard ; Sharma, Sunil ; Shibata, David ; Skibber, John M. ; Sofocleous, Constantinos T. ; Stoffel, Elena M. ; Stotsky-Himelfarb, Eden ; Willett, Christopher G. ; Gregory, Kristina M. ; Freedman-Cass, Deborah A. / Colon cancer, version 3.2014. In: JNCCN Journal of the National Comprehensive Cancer Network. 2014 ; Vol. 12, No. 7. pp. 1028-1059.
@article{b5f92b9c27f84917a7724d6118d3056d,
title = "Colon cancer, version 3.2014",
abstract = "The NCCN Guidelines for Colon Cancer address diagnosis, pathologic staging, surgical management, perioperative treatment, posttreatment surveillance, management of recurrent and metastatic disease,and survivorship. This portion of the guidelines focuses on the use of systemic therapy in metastatic disease. The management of metastatic colorectal cancer involves a continuum of care in which patients are exposed sequentially to a variety of active agents, either in combinations or as single agents. Choice of therapy is based on the goals of treatment, the type and timing of prior therapy, the different efficacy and toxicity profiles of the drugs, the mutational status of the tumor, and patient preference.",
author = "Benson, {Al B.} and Venook, {Alan P.} and Tanios Bekaii-Saab and Emily Chan and Chen, {Yi Jen} and Cooper, {Harry S.} and Engstrom, {Paul F.} and Enzinger, {Peter C.} and Fenton, {Moon J.} and Fuchs, {Charles S.} and Grem, {Jean L.} and Steven Hunt and Ahmed Kamel and Leong, {Lucille A.} and Edward Lin and Wells Messersmith and Mulcahy, {Mary F.} and Murphy, {James D.} and Steven Nurkin and Eric Rohren and Ryan, {David P.} and Leonard Saltz and Sunil Sharma and David Shibata and Skibber, {John M.} and Sofocleous, {Constantinos T.} and Stoffel, {Elena M.} and Eden Stotsky-Himelfarb and Willett, {Christopher G.} and Gregory, {Kristina M.} and Freedman-Cass, {Deborah A.}",
year = "2014",
month = "7",
day = "1",
doi = "10.6004/jnccn.2014.0099",
language = "English (US)",
volume = "12",
pages = "1028--1059",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "7",

}

TY - JOUR

T1 - Colon cancer, version 3.2014

AU - Benson, Al B.

AU - Venook, Alan P.

AU - Bekaii-Saab, Tanios

AU - Chan, Emily

AU - Chen, Yi Jen

AU - Cooper, Harry S.

AU - Engstrom, Paul F.

AU - Enzinger, Peter C.

AU - Fenton, Moon J.

AU - Fuchs, Charles S.

AU - Grem, Jean L.

AU - Hunt, Steven

AU - Kamel, Ahmed

AU - Leong, Lucille A.

AU - Lin, Edward

AU - Messersmith, Wells

AU - Mulcahy, Mary F.

AU - Murphy, James D.

AU - Nurkin, Steven

AU - Rohren, Eric

AU - Ryan, David P.

AU - Saltz, Leonard

AU - Sharma, Sunil

AU - Shibata, David

AU - Skibber, John M.

AU - Sofocleous, Constantinos T.

AU - Stoffel, Elena M.

AU - Stotsky-Himelfarb, Eden

AU - Willett, Christopher G.

AU - Gregory, Kristina M.

AU - Freedman-Cass, Deborah A.

PY - 2014/7/1

Y1 - 2014/7/1

N2 - The NCCN Guidelines for Colon Cancer address diagnosis, pathologic staging, surgical management, perioperative treatment, posttreatment surveillance, management of recurrent and metastatic disease,and survivorship. This portion of the guidelines focuses on the use of systemic therapy in metastatic disease. The management of metastatic colorectal cancer involves a continuum of care in which patients are exposed sequentially to a variety of active agents, either in combinations or as single agents. Choice of therapy is based on the goals of treatment, the type and timing of prior therapy, the different efficacy and toxicity profiles of the drugs, the mutational status of the tumor, and patient preference.

AB - The NCCN Guidelines for Colon Cancer address diagnosis, pathologic staging, surgical management, perioperative treatment, posttreatment surveillance, management of recurrent and metastatic disease,and survivorship. This portion of the guidelines focuses on the use of systemic therapy in metastatic disease. The management of metastatic colorectal cancer involves a continuum of care in which patients are exposed sequentially to a variety of active agents, either in combinations or as single agents. Choice of therapy is based on the goals of treatment, the type and timing of prior therapy, the different efficacy and toxicity profiles of the drugs, the mutational status of the tumor, and patient preference.

UR - http://www.scopus.com/inward/record.url?scp=84903980978&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903980978&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2014.0099

DO - 10.6004/jnccn.2014.0099

M3 - Article

C2 - 24994923

AN - SCOPUS:84903980978

VL - 12

SP - 1028

EP - 1059

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

SN - 1540-1405

IS - 7

ER -